Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

BACKGROUND: In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Blomstrand, Hakon, Scheibling, Ursula, Bratthäll, Charlotte, Green, Henrik, Elander, Nils O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325739/
https://www.ncbi.nlm.nih.gov/pubmed/30621618
http://dx.doi.org/10.1186/s12885-018-5244-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325739/
https://www.ncbi.nlm.nih.gov/pubmed/30621618
http://dx.doi.org/10.1186/s12885-018-5244-2

Ejemplares similares